Sign In
Buy NDAQ
$81.61
-0.88 (-1.07%)
At Close: Jun 24, 2026
History Says the Nasdaq Could Soar Again in 2025: 1 Artificial Intelligence (AI) Stock-Split Stock to Buy Before That Happens
05:05am, Saturday, 11'th Jan 2025
Following a solid couple of years in 2023 and 2024, it wouldn't be surprising to see the Nasdaq Composite index fly higher in the new year. It could grow due to several factors, such as strong economi
History Says the Nasdaq Will Soar in 2025. 2 Brilliant Tech Stocks to Buy Before It Does.
03:02am, Saturday, 11'th Jan 2025
As we roll into a new year, investors are taking stock of the market's performance, and there's much to be thankful for. The Nasdaq Composite (^IXIC -1.63%) led the major indexes higher last year, ris
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:30pm, Friday, 10'th Jan 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Friday, 10'th Jan 2025
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-q
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of BIMI International Medical Inc. BIMI International Medical Inc.'s stock w
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 10'th Jan 2025
Craig Swandal, experienced medical device manufacturing executive, joins leadership team Craig Swandal, experienced medical device manufacturing executive, joins leadership team
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 10'th Jan 2025
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 10'th Jan 2025
SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 8, 2025, the Company granted 15,000 restricted
Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date December 31, 2024
04:05pm, Friday, 10'th Jan 2025
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of December 31, 2024, short interest in 3,085 Nasdaq Global MarketSM securities totaled 12,137,206,474 shares compared wit
3 E Network Technology Group Limited Announces Closing of Nasdaq Initial Public Offering
02:00pm, Friday, 10'th Jan 2025
Guangzhou, China, Jan. 10, 2025 (GLOBE NEWSWIRE) -- 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3e Network”), a business-to-business (“B2B”) information technolo
Nasdaq Down Over 2%; Walgreens Posts Upbeat Results
12:51pm, Friday, 10'th Jan 2025
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 400 points on Friday.
Constellation Energy, A Nasdaq-100 Nuclear Stock, Appears Ripe For Future Gains Following Calpine Deal
11:11am, Friday, 10'th Jan 2025
With bullish technical indicators supporting its stock momentum and a transformative acquisition underway, Constellation Energy Corp.‘s CEG stock appears primed for future gains following its $26.6
EpicQuest Education Regains Compliance with Nasdaq Minimum Bid Price Requirement
09:00am, Friday, 10'th Jan 2025
MIDDLETOWN, Ohio , Jan. 10, 2025 /PRNewswire/ -- EpicQuest Education Group International Limited (Nasdaq: EEIQ), ("EpicQuest Education", "EEIQ" or the "Company"), a provider of higher education for d
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03:38pm, Thursday, 09'th Jan 2025
NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical
Will Nasdaq (NDAQ) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Thursday, 09'th Jan 2025
Nasdaq (NDAQ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
